Nuclear medicine testing is an important test that quantifies various functions and metabolism of human organs as images or graphs to provide not only morphological images but also functional information. In nuclear medicine diagnosis, radiopharmaceuticals are administered into the body and the target atoms are integrated in the given organ, which is then analyzed by means of time and image to obtain the function and properties of the organ. As a result, a foreign body is introduced in the body, and the measurement of drug must be done properly in order to avoid any unexpected phenomenon in the body.
The dose of radiopharmaceuticals is determined primarily by considering diagnostic information such as image quality, patient damage dose, test time, etc. In other words, the minimum dose available for diagnostic validation is set to be possible. Usually, in the case of radiopharmaceuticals with high enrichment for target organs or radioactive drugs labeled with relatively long half-life nuclides, low dose (radiation capacity) is set.
Kim Min U, a researcher at the Bioengineering Institute, has conducted a theoretical study of the type and decay characteristics of medical radiopharmaceuticals used in nuclear medicine, and presented a new method of spectral analysis available for medical radiopharmaceutical measurement.
First, he described a new baseline restorer with improved baseline recovery characteristics for radiation signals. Then, he performed a radiation spectrum analysis by using a new algorithm for peak detection and radioisotope estimation.
He conducted an analysis in two steps. First, he detected the photoelectric peak in the measured radiation spectrum using wavelet transform. Then, he compared the peaks detected using fuzzy inference with those of the previously published isotope peak library.
He compared the performance of the new spectral analysis method with the results of multiple regression analysis, which showed that the new method is superior.
© 2021 Kim Chaek University of Technology